Skip to main content
OpenTrials
Completed

NCT Number: NCT06549608

A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

This real-world study will describe the demographic and clinical characteristics and mavacamten treatment of adult patients with obstructive hypertrophic cardiomyopathy who participated in the Bristol-Myers Squibb (BMS)-sponsored CAMZYOS Patient Support Program in Canada.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertrophic Cardiomyopathy Aortic Stenosis, Subvalvular Aortic Valve Disease Aortic Valve Stenosis Cardiomyopathies Cardiomyopathy, Hypertrophic Cardiovascular Diseases Heart Diseases Heart Valve Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

St. Paul's Hospital

Vancouver, British Columbia, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants ≥18 years of age.
  • Participants who have initiated mavacamten as part of routine clinical care, through the BMS-sponsored CAMZYOS Patient Support Program for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
  • Participants who consented to the use of their de-identified data, generated from information collected in the course of the program.

Exclusion criteria

  • There are no exclusion criteria.

Treatment and study plan

Mavacamten

Drug

As per product label

Primary outcomes

  1. Participant demographics

    Time frame: Baseline

  2. Participant clinical characteristics

    Time frame: Baseline

Secondary outcomes

  1. Dose regimen of mavacamten treatment

    Time frame: Every 3-months up to 14 months

  2. Titration patterns of mavacamten treatment

    Time frame: Up to 14 months

  3. Mavacamten treatment duration

    Time frame: Up to 14 months

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Official study title

Patient Characteristics and Treatment Duration of Mavacamten Obstructive HCM Patient Support Program in Canada: A Retrospective Cohort Study

Important dates

Study start
2024
Primary completion
2024
Study completion
2025
First posted
Aug 12, 2024
Registry last updated
Jun 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.